Revvity, a global provider of health science solutions, has announced the launch of the automated tuberculosis testing platform, Auto-Pure 2400 liquid handler, for use with the T-SPOT.TB test.

The integration of Revvity's T-SPOT.TB test with the Auto-Pure 2400 liquid handling platform from Allsheng marks a significant advancement in the field of tuberculosis testing.

This new automated tuberculosis testing platform is designed for ease of use and provides efficient workflows in the lab. It also enhances productivity by reducing hands-on time for technicians.

The platform's intuitive software interface further simplifies the workflow.

Equipped with magnetic cell isolation technology, the Auto-Pure 2400 system is tailored for processing up to 24 samples per run.

It can complete the day-one workflow of the T-SPOT.TB test in less than three and a half hours, requiring only one mid-run interaction from the user.

The T-SPOT.TB test is developed for detecting latent tuberculosis infection (LTBI). It is an interferon-gamma release assay (IGRA) based on the enzyme-linked immunospot technology.

The test's rigorous protocol includes washing, isolating, and counting peripheral blood mononuclear cells (PBMCs) before the test.

Revvity infectious diseases general manager Darren Sher said: “The ability to use the Auto-Pure 2400 platform with our T-SPOT.TB test provides labs with an efficient workflow, allowing latent TB testing to be run in a mid-high-volume setting, without having to compromise on the clinical performance of the test.

“With this solution, more labs can offer clinicians access to the most accurate TB diagnostic on the market.”

Last month, Revvity unveiled a new ‘sample-to-answer’ workflow designed to accelerate newborn sequencing research.

This research-use-only, flexible end-to-end workflow solution is intended to allow users to utilise different reagents, instruments, and databases based on the needs of a laboratory.